Bli medlem
Bli medlem

Du är här

2021-10-28

Immunicum AB (publ) Interim Report July - Sep 2021

Press Release

28 October 2021

Immunicum AB (publ) Interim Report July - Sep 2021

FINANCIAL SUMMARY FOR THE QUARTER JULY - SEP

  • Net sales for the period amounted to KSEK -245 (-).
  • Result for the quarter amounted to KSEK -26,866 (-15,960).
  • Earnings/loss per share and diluted earnings per share totaled SEK -0,13 (-0,22).

SIGNIFICANT EVENTS DURING THE QUARTER

CORPORATE

  • Immunicum announced the outcome of the subscription of employee stock options and restricted share units in the incentive program LTI 2021/2024 resolved by the Annual General Meeting on 4 May 2021. In total, 1,286,092 employee stock options and 660,000 restricted share units have been subscribed, representing a dilution of 0.97 percent if all employee stock options and restricted share units are exercised.
  • Immunicum announced the appointment of Ada M. Kruisbeek, PhD, Sjoerd H. van der Burg, PhD, and Tanja D. de Gruijl, PhD, to its Scientific Advisory Board (SAB). The leading experts in cancer immunology were previously members of the SAB of DCprime and join existing Immunicum SAB members, Inge Marie Svane, MD, PhD, and Pawel Kalinski, MD, PhD. Dr Kruisbeek serves as chair of the SAB.
  • Alex Karlsson-Parra, Chief Scientific Officer at Immunicum, attended the 6th CAR-TCR Summit as an expert speaker in a workshop on 30 August. He presented the potential use of Immunicum’s platforms ilixadencel and DCOne® to improve the quality of T cells for CAR-T and other adoptive T cell-based cancer therapies.
  • Chief Executive Officer, Erik Manting, presented at the Pareto Securities’ 12th Annual Healthcare Conference, September 1-2.

CLINICAL

  • Immunicum received a positive recommendation by the Data Safety and Monitoring Board (DSMB) for the use of ilixadencel in combination with an immune checkpoint inhibitor, pembrolizumab, based on the ongoing Phase Ib part of the ILIAD clinical study in multiple solid tumor indications.

PRECLINICAL

  • Immunicum announced a new research collaboration with the University Medical Center Groningen (UMCG), to explore novel treatment options for ovarian cancer based on the combination of Immunicum’s cell-based cancer vaccine platform with immune checkpoint inhibitors (CPI). The project is supported by a grant from Health~Holland, Top Sector Life Sciences & Health (LSH).

COVID-19 STATEMENT

  • Immunicum has taken action to minimize the effect of the COVID-19 situation on operations.

FINANCIAL SUMMARY

 July - SepJuly - SepFull year
KSEK unless otherwise stated20212020202120202020
Operating profit/loss-26,297-15,524-98,354-39,382-86,027
Net profit/loss-26,866-15,960-100,567-41,368-89,248
Earnings per share, before and after dilution (SEK)-0,13-0,22-0,56-0,56-1,17
Cash181,50413,620181,50413,620167,643
Shareholders equity688,986
Författare GlobeNewswire